CN1016169B - 制备药用咪唑衍生物的方法 - Google Patents
制备药用咪唑衍生物的方法Info
- Publication number
- CN1016169B CN1016169B CN88101452A CN88101452A CN1016169B CN 1016169 B CN1016169 B CN 1016169B CN 88101452 A CN88101452 A CN 88101452A CN 88101452 A CN88101452 A CN 88101452A CN 1016169 B CN1016169 B CN 1016169B
- Authority
- CN
- China
- Prior art keywords
- tert
- hydroxy
- formula
- imidazole
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000002460 imidazoles Chemical class 0.000 title claims abstract description 7
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 56
- 239000001257 hydrogen Substances 0.000 claims abstract description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 27
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 18
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims description 29
- DOZRDZLFLOODMB-UHFFFAOYSA-N 3,5-di-tert-Butyl-4-hydroxybenzaldehyde Chemical compound CC(C)(C)C1=CC(C=O)=CC(C(C)(C)C)=C1O DOZRDZLFLOODMB-UHFFFAOYSA-N 0.000 claims description 18
- VMOHIPREBNMMPR-UHFFFAOYSA-N 2,6-ditert-butyl-4-[(imidazol-1-ylamino)methyl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CNN2C=NC=C2)=C1 VMOHIPREBNMMPR-UHFFFAOYSA-N 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- GSWMBQGISKRFQD-UHFFFAOYSA-N 2,6-ditert-butyl-4-(imidazol-1-yliminomethyl)phenol Chemical compound OC1=C(C=C(C=NN2C=NC=C2)C=C1C(C)(C)C)C(C)(C)C GSWMBQGISKRFQD-UHFFFAOYSA-N 0.000 claims description 8
- KUMCEXXJHWNRGG-UHFFFAOYSA-N 2,6-ditert-butyl-4-[(2-methylimidazol-1-yl)iminomethyl]phenol Chemical compound OC1=C(C=C(C=NN2C(=NC=C2)C)C=C1C(C)(C)C)C(C)(C)C KUMCEXXJHWNRGG-UHFFFAOYSA-N 0.000 claims description 6
- FZPQUTPEWLVKLO-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[(2-methylimidazol-1-yl)amino]methyl]phenol Chemical compound CC1=NC=CN1NCC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FZPQUTPEWLVKLO-UHFFFAOYSA-N 0.000 claims description 5
- XTWACBKKQAVXAZ-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[(2-methylsulfanylimidazol-1-yl)amino]methyl]phenol Chemical compound CSC1=NC=CN1NCC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 XTWACBKKQAVXAZ-UHFFFAOYSA-N 0.000 claims description 5
- YDTYEXZZKXRTNG-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[(2-propylimidazol-1-yl)amino]methyl]phenol Chemical compound CCCC1=NC=CN1NCC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 YDTYEXZZKXRTNG-UHFFFAOYSA-N 0.000 claims description 3
- DDLBKNDIAWPNLN-UHFFFAOYSA-N 3,5-ditert-butyl-4-hydroxy-n-(2-methylimidazol-1-yl)benzamide Chemical compound CC1=NC=CN1NC(=O)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 DDLBKNDIAWPNLN-UHFFFAOYSA-N 0.000 claims description 3
- LNGYKKPJUPSRTA-UHFFFAOYSA-N 3,5-ditert-butyl-4-hydroxy-n-imidazol-1-ylbenzamide Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C(=O)NN2C=NC=C2)=C1 LNGYKKPJUPSRTA-UHFFFAOYSA-N 0.000 claims description 3
- 238000007126 N-alkylation reaction Methods 0.000 claims description 3
- 150000001299 aldehydes Chemical class 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- MXZANEWAFZMPKW-UHFFFAOYSA-N imidazol-1-amine Chemical compound NN1C=CN=C1 MXZANEWAFZMPKW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 abstract description 24
- 239000002253 acid Substances 0.000 abstract description 22
- 206010030113 Oedema Diseases 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 147
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 100
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 99
- 239000000243 solution Substances 0.000 description 92
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 74
- 239000000203 mixture Substances 0.000 description 57
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 55
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 238000002844 melting Methods 0.000 description 23
- 230000008018 melting Effects 0.000 description 23
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 20
- 238000003756 stirring Methods 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000001816 cooling Methods 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 13
- -1 piperidino, morpholino Chemical group 0.000 description 13
- 238000006722 reduction reaction Methods 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 5
- 238000006356 dehydrogenation reaction Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 210000003281 pleural cavity Anatomy 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 210000000416 exudates and transudate Anatomy 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- QAEKVJNQDKJVGB-UHFFFAOYSA-N imidazol-1-amine;hydrochloride Chemical compound Cl.NN1C=CN=C1 QAEKVJNQDKJVGB-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- OHMONANWZVAESU-UHFFFAOYSA-N n-[(3,5-ditert-butyl-4-hydroxyphenyl)methyl]-n-imidazol-1-ylformamide Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CN(C=O)N2C=NC=C2)=C1 OHMONANWZVAESU-UHFFFAOYSA-N 0.000 description 4
- OABMAWFFLNXVDL-UHFFFAOYSA-M n-[3-(benzylideneamino)imidazol-3-ium-1-yl]-1-phenylmethanimine;chloride Chemical compound [Cl-].C=1C=CC=CC=1C=NN(C=1)C=C[N+]=1N=CC1=CC=CC=C1 OABMAWFFLNXVDL-UHFFFAOYSA-M 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000001256 steam distillation Methods 0.000 description 4
- 238000000859 sublimation Methods 0.000 description 4
- 230000008022 sublimation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KAJICSGLHKRDLN-UHFFFAOYSA-N 1,3-dicyclohexylthiourea Chemical compound C1CCCCC1NC(=S)NC1CCCCC1 KAJICSGLHKRDLN-UHFFFAOYSA-N 0.000 description 3
- COWTXDKTZHVPGV-UHFFFAOYSA-N 2,6-ditert-butyl-4-[(2-morpholin-4-ylimidazol-1-yl)iminomethyl]phenol Chemical compound OC1=C(C=C(C=NN2C(=NC=C2)N2CCOCC2)C=C1C(C)(C)C)C(C)(C)C COWTXDKTZHVPGV-UHFFFAOYSA-N 0.000 description 3
- RESSNZDKUDYAAC-UHFFFAOYSA-N 2,6-ditert-butyl-4-[(2-propylimidazol-1-yl)iminomethyl]phenol Chemical compound OC1=C(C=C(C=NN2C(=NC=C2)CCC)C=C1C(C)(C)C)C(C)(C)C RESSNZDKUDYAAC-UHFFFAOYSA-N 0.000 description 3
- RDVUAQCQQRYNFF-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[imidazol-1-yl(methyl)amino]methyl]phenol Chemical compound C1=CN=CN1N(C)CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 RDVUAQCQQRYNFF-UHFFFAOYSA-N 0.000 description 3
- HYMMYWDBZIVKMM-UHFFFAOYSA-N 2-methyl-1h-imidazol-3-ium-3-amine;chloride Chemical compound Cl.CC1=NC=CN1N HYMMYWDBZIVKMM-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 241000206575 Chondrus crispus Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 230000003501 anti-edematous effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 210000000224 granular leucocyte Anatomy 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- JSIVBVHQFFIWAQ-UHFFFAOYSA-N n-imidazol-1-yl-1-phenylmethanimine Chemical compound C=1C=CC=CC=1C=NN1C=CN=C1 JSIVBVHQFFIWAQ-UHFFFAOYSA-N 0.000 description 3
- 239000003791 organic solvent mixture Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- HPRRRCJCXROIAC-UHFFFAOYSA-N 1,1-diethoxy-2-isothiocyanatoethane Chemical compound CCOC(OCC)CN=C=S HPRRRCJCXROIAC-UHFFFAOYSA-N 0.000 description 2
- LNTNYYZBFMNYEY-UHFFFAOYSA-N 1,3-bis(benzylideneamino)imidazole-2-thione Chemical compound S=C1N(N=CC=2C=CC=CC=2)C=CN1N=CC1=CC=CC=C1 LNTNYYZBFMNYEY-UHFFFAOYSA-N 0.000 description 2
- PICDEBOSKLPILF-UHFFFAOYSA-N 1-amino-3-(2,2-diethoxyethyl)thiourea Chemical compound CCOC(OCC)CNC(=S)NN PICDEBOSKLPILF-UHFFFAOYSA-N 0.000 description 2
- JSYBIQNJCPPGIA-UHFFFAOYSA-N 1-phenyl-n-(2-propan-2-ylimidazol-1-yl)methanimine Chemical compound CC(C)C1=NC=CN1N=CC1=CC=CC=C1 JSYBIQNJCPPGIA-UHFFFAOYSA-N 0.000 description 2
- VRZIOKCPJIHBOQ-UHFFFAOYSA-N 1-phenyl-n-(2-propylimidazol-1-yl)methanimine Chemical compound CCCC1=NC=CN1N=CC1=CC=CC=C1 VRZIOKCPJIHBOQ-UHFFFAOYSA-N 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 2
- UTMMCAYDNFBEOF-UHFFFAOYSA-N 2,6-ditert-butyl-4-[(2-methylsulfanylimidazol-1-yl)iminomethyl]phenol Chemical compound OC1=C(C=C(C=NN2C(=NC=C2)SC)C=C1C(C)(C)C)C(C)(C)C UTMMCAYDNFBEOF-UHFFFAOYSA-N 0.000 description 2
- NKJKBRALSSHIPF-UHFFFAOYSA-N 2,6-ditert-butyl-4-[(2-propan-2-ylimidazol-1-yl)iminomethyl]phenol Chemical compound OC1=C(C=C(C=NN2C(=NC=C2)C(C)C)C=C1C(C)(C)C)C(C)(C)C NKJKBRALSSHIPF-UHFFFAOYSA-N 0.000 description 2
- VATGYSQJKDYHKS-UHFFFAOYSA-N 2,6-ditert-butyl-4-[(4-methylimidazol-1-yl)iminomethyl]phenol Chemical compound OC1=C(C=C(C=NN2C=NC(=C2)C)C=C1C(C)(C)C)C(C)(C)C VATGYSQJKDYHKS-UHFFFAOYSA-N 0.000 description 2
- AKNICOBZERXTKJ-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[(2-morpholin-4-ylimidazol-1-yl)amino]methyl]phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CNN2C(=NC=C2)N2CCOCC2)=C1 AKNICOBZERXTKJ-UHFFFAOYSA-N 0.000 description 2
- XOWYDVGDZACKBC-UHFFFAOYSA-N 2,6-ditert-butyl-4-[[(4-methylimidazol-1-yl)amino]methyl]phenol Chemical compound C1=NC(C)=CN1NCC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 XOWYDVGDZACKBC-UHFFFAOYSA-N 0.000 description 2
- NPHFBOCZQCPJPO-UHFFFAOYSA-N 2-methylsulfanylimidazol-1-amine Chemical compound CSC1=NC=CN1N NPHFBOCZQCPJPO-UHFFFAOYSA-N 0.000 description 2
- SYSZVJJJUNLSIT-UHFFFAOYSA-N 2-propan-2-ylimidazol-1-amine;hydrochloride Chemical compound Cl.CC(C)C1=NC=CN1N SYSZVJJJUNLSIT-UHFFFAOYSA-N 0.000 description 2
- RJLPTPYWXKURMZ-UHFFFAOYSA-N 2-propylimidazol-1-amine;hydrochloride Chemical compound Cl.CCCC1=NC=CN1N RJLPTPYWXKURMZ-UHFFFAOYSA-N 0.000 description 2
- AIPCSKRJJOUNEM-UHFFFAOYSA-N 3,5-ditert-butyl-4-hydroxybenzoyl chloride Chemical compound CC(C)(C)C1=CC(C(Cl)=O)=CC(C(C)(C)C)=C1O AIPCSKRJJOUNEM-UHFFFAOYSA-N 0.000 description 2
- WLEIMLFYCYDAAZ-UHFFFAOYSA-N 3-(benzylideneamino)-1h-imidazole-2-thione Chemical compound SC1=NC=CN1N=CC1=CC=CC=C1 WLEIMLFYCYDAAZ-UHFFFAOYSA-N 0.000 description 2
- FDHARSGSKIRQTF-UHFFFAOYSA-N 4-methylimidazol-1-amine;hydrochloride Chemical compound Cl.CC1=CN(N)C=N1 FDHARSGSKIRQTF-UHFFFAOYSA-N 0.000 description 2
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000002027 dichloromethane extract Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- ANCMHCSMOLJUKI-UHFFFAOYSA-N n-(2-methylimidazol-1-yl)-1-phenylmethanimine Chemical compound CC1=NC=CN1N=CC1=CC=CC=C1 ANCMHCSMOLJUKI-UHFFFAOYSA-N 0.000 description 2
- GSGZXTYZNYSRFR-UHFFFAOYSA-N n-(2-methylsulfanylimidazol-1-yl)-1-phenylmethanimine Chemical compound CSC1=NC=CN1N=CC1=CC=CC=C1 GSGZXTYZNYSRFR-UHFFFAOYSA-N 0.000 description 2
- IKGNTONVJGUQGR-UHFFFAOYSA-N n-(2-morpholin-4-ylimidazol-1-yl)-1-phenylmethanimine Chemical compound C1COCCN1C1=NC=CN1N=CC1=CC=CC=C1 IKGNTONVJGUQGR-UHFFFAOYSA-N 0.000 description 2
- MOOUBHZGTDUWPC-UHFFFAOYSA-N n-(4-methylimidazol-1-yl)-1-phenylmethanimine Chemical compound C1=NC(C)=CN1N=CC1=CC=CC=C1 MOOUBHZGTDUWPC-UHFFFAOYSA-N 0.000 description 2
- IUBGBBUXBCLQNQ-UHFFFAOYSA-M n-[3-(benzylideneamino)-2-methylimidazol-3-ium-1-yl]-1-phenylmethanimine;chloride Chemical compound [Cl-].CC=1N(N=CC=2C=CC=CC=2)C=C[N+]=1N=CC1=CC=CC=C1 IUBGBBUXBCLQNQ-UHFFFAOYSA-M 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- USVVENVKYJZFMW-ONEGZZNKSA-N (e)-carboxyiminocarbamic acid Chemical compound OC(=O)\N=N\C(O)=O USVVENVKYJZFMW-ONEGZZNKSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- LFDGRWDETVOGDT-UHFFFAOYSA-N 1h-pyrrole;hydrochloride Chemical compound Cl.C=1C=CNC=1 LFDGRWDETVOGDT-UHFFFAOYSA-N 0.000 description 1
- HJKLEAOXCZIMPI-UHFFFAOYSA-N 2,2-diethoxyethanamine Chemical compound CCOC(CN)OCC HJKLEAOXCZIMPI-UHFFFAOYSA-N 0.000 description 1
- USAYMJGCALIGIG-UHFFFAOYSA-N 2,3-dichlorocyclohexa-2,5-diene-1,4-dione Chemical compound ClC1=C(Cl)C(=O)C=CC1=O USAYMJGCALIGIG-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- OUWCEOVUIOPRKQ-UHFFFAOYSA-N 2-methylimidazol-1-amine Chemical compound CC1=NC=CN1N OUWCEOVUIOPRKQ-UHFFFAOYSA-N 0.000 description 1
- NHCFOPUKQOGEOB-UHFFFAOYSA-N 2-morpholin-4-ylimidazol-1-amine Chemical compound NN1C=CN=C1N1CCOCC1 NHCFOPUKQOGEOB-UHFFFAOYSA-N 0.000 description 1
- FUOZJYASZOSONT-UHFFFAOYSA-N 2-propan-2-yl-1h-imidazole Chemical compound CC(C)C1=NC=CN1 FUOZJYASZOSONT-UHFFFAOYSA-N 0.000 description 1
- MKBBSFGKFMQPPC-UHFFFAOYSA-N 2-propyl-1h-imidazole Chemical compound CCCC1=NC=CN1 MKBBSFGKFMQPPC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical class [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910010277 boron hydride Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- OAOPDYUHWPBJCW-UHFFFAOYSA-N cyanoboron;sodium Chemical compound [Na].[B]C#N OAOPDYUHWPBJCW-UHFFFAOYSA-N 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229940097789 heavy mineral oil Drugs 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YLACRFYIUQZNIV-UHFFFAOYSA-N o-(2,4-dinitrophenyl)hydroxylamine Chemical compound NOC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O YLACRFYIUQZNIV-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QDNCLIPKBNMUPP-UHFFFAOYSA-N trimethyloxidanium Chemical compound C[O+](C)C QDNCLIPKBNMUPP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Resins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1073/87 | 1987-03-20 | ||
| CH107387 | 1987-03-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN88101452A CN88101452A (zh) | 1988-10-05 |
| CN1016169B true CN1016169B (zh) | 1992-04-08 |
Family
ID=4201822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN88101452A Expired CN1016169B (zh) | 1987-03-20 | 1988-03-19 | 制备药用咪唑衍生物的方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4908363A (enExample) |
| EP (1) | EP0283857B1 (enExample) |
| JP (1) | JPS63253070A (enExample) |
| KR (1) | KR880011117A (enExample) |
| CN (1) | CN1016169B (enExample) |
| AT (1) | ATE73777T1 (enExample) |
| AU (1) | AU613349B2 (enExample) |
| CS (1) | CS276093B6 (enExample) |
| DE (1) | DE3869163D1 (enExample) |
| DK (1) | DK59888A (enExample) |
| ES (1) | ES2032482T3 (enExample) |
| FI (1) | FI880813A7 (enExample) |
| GR (1) | GR3004729T3 (enExample) |
| HU (1) | HU201312B (enExample) |
| IL (1) | IL85725A (enExample) |
| MC (1) | MC1919A1 (enExample) |
| MX (1) | MX10721A (enExample) |
| NO (1) | NO170215C (enExample) |
| NZ (1) | NZ223862A (enExample) |
| PT (1) | PT87025B (enExample) |
| SU (1) | SU1657057A3 (enExample) |
| YU (1) | YU46444B (enExample) |
| ZA (1) | ZA881810B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5073566A (en) * | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| US5574057A (en) * | 1993-02-03 | 1996-11-12 | University Of Utah Research Foundation | Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent |
| US5523310A (en) * | 1994-12-05 | 1996-06-04 | Hoffmann-La Roche Inc. | 1,2,3-triazole derivatives |
| AU1383200A (en) | 1998-11-23 | 2000-06-13 | F. Hoffmann-La Roche Ag | Synthesis of anti-inflammatory (1,2,3)triazoles |
| DE10132896A1 (de) * | 2001-07-06 | 2003-01-16 | Bayer Cropscience Ag | Heterocyclische Amidderivate |
| WO2003010143A1 (en) * | 2001-07-26 | 2003-02-06 | Samsung Electronics Co., Ltd. | Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses |
| JP2004196795A (ja) * | 2002-12-16 | 2004-07-15 | Wyeth | 外部寄生虫駆除剤としてのｎ−フェニル−３−シクロプロピルピラゾール−４−カルボニトリル |
| EP1431292A1 (en) * | 2002-12-16 | 2004-06-23 | Laboratoire Theramex | 1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3152228A1 (de) * | 1980-07-31 | 1983-01-13 | L Blinov | Derivatives of 2,2-azoimidazole,method for the preparation thereof,liquid crystal material and electro-optical device |
| DE3674054D1 (de) * | 1985-04-26 | 1990-10-18 | Hoffmann La Roche | 1,3-disubstituierte imidazoliumsalze. |
| ZW6687A1 (en) * | 1986-05-13 | 1987-12-02 | Hoffmann La Roche | 1,3-disubstituted imidazolium salts |
| MW7087A1 (en) * | 1986-10-03 | 1988-05-11 | Hoffmann La Roche | 1,3-disubstituted imidazolium salts |
| WO1988007040A1 (en) * | 1987-03-20 | 1988-09-22 | E.I. Du Pont De Nemours And Company | Fungicidal aminotriazoles and aminoimidazoles |
-
1988
- 1988-02-05 DK DK059888A patent/DK59888A/da not_active Application Discontinuation
- 1988-02-12 CS CS88891A patent/CS276093B6/cs unknown
- 1988-02-22 FI FI880813A patent/FI880813A7/fi not_active Application Discontinuation
- 1988-03-01 YU YU40388A patent/YU46444B/sh unknown
- 1988-03-09 EP EP88103746A patent/EP0283857B1/de not_active Expired - Lifetime
- 1988-03-09 ES ES198888103746T patent/ES2032482T3/es not_active Expired - Lifetime
- 1988-03-09 AT AT88103746T patent/ATE73777T1/de active
- 1988-03-09 DE DE8888103746T patent/DE3869163D1/de not_active Expired - Lifetime
- 1988-03-10 MX MX1072188A patent/MX10721A/es unknown
- 1988-03-11 NZ NZ223862A patent/NZ223862A/xx unknown
- 1988-03-14 ZA ZA881810A patent/ZA881810B/xx unknown
- 1988-03-14 IL IL85725A patent/IL85725A/xx unknown
- 1988-03-15 US US07/169,207 patent/US4908363A/en not_active Expired - Fee Related
- 1988-03-16 HU HU881238A patent/HU201312B/hu not_active IP Right Cessation
- 1988-03-17 MC MC881959A patent/MC1919A1/fr unknown
- 1988-03-18 JP JP63063734A patent/JPS63253070A/ja active Pending
- 1988-03-18 PT PT87025A patent/PT87025B/pt not_active IP Right Cessation
- 1988-03-18 SU SU884355836A patent/SU1657057A3/ru active
- 1988-03-18 NO NO881199A patent/NO170215C/no unknown
- 1988-03-19 CN CN88101452A patent/CN1016169B/zh not_active Expired
- 1988-03-19 KR KR1019880002924A patent/KR880011117A/ko not_active Withdrawn
- 1988-03-21 AU AU13532/88A patent/AU613349B2/en not_active Ceased
-
1992
- 1992-05-27 GR GR920401077T patent/GR3004729T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL85725A (en) | 1991-12-12 |
| CS8800891A2 (en) | 1990-09-12 |
| PT87025A (pt) | 1988-04-01 |
| EP0283857A1 (de) | 1988-09-28 |
| EP0283857B1 (de) | 1992-03-18 |
| NO881199L (no) | 1988-09-21 |
| NO170215B (no) | 1992-06-15 |
| NZ223862A (en) | 1990-08-28 |
| CS276093B6 (en) | 1992-04-15 |
| DK59888A (da) | 1988-09-21 |
| YU46444B (sh) | 1993-10-20 |
| DK59888D0 (da) | 1988-02-05 |
| JPS63253070A (ja) | 1988-10-20 |
| IL85725A0 (en) | 1988-08-31 |
| ES2032482T3 (es) | 1993-02-16 |
| NO170215C (no) | 1992-09-23 |
| FI880813A7 (fi) | 1988-09-21 |
| MC1919A1 (fr) | 1989-04-06 |
| KR880011117A (ko) | 1988-10-26 |
| PT87025B (pt) | 1992-06-30 |
| ATE73777T1 (de) | 1992-04-15 |
| DE3869163D1 (de) | 1992-04-23 |
| SU1657057A3 (ru) | 1991-06-15 |
| HU201312B (en) | 1990-10-28 |
| MX10721A (es) | 1993-09-01 |
| CN88101452A (zh) | 1988-10-05 |
| US4908363A (en) | 1990-03-13 |
| YU40388A (en) | 1990-02-28 |
| HUT49581A (en) | 1989-10-30 |
| NO881199D0 (no) | 1988-03-18 |
| ZA881810B (en) | 1988-09-20 |
| AU613349B2 (en) | 1991-08-01 |
| FI880813A0 (fi) | 1988-02-22 |
| GR3004729T3 (enExample) | 1993-04-28 |
| AU1353288A (en) | 1988-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2230936C (en) | 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists | |
| CN1035616C (zh) | 异羟肟酸衍生物 | |
| CN1043762C (zh) | 用作兴奋性氨基酸受体拮抗剂的化合物及其药物组合物 | |
| US5268375A (en) | Dinitrogen heterocyclic derivatives N-substituted by a biphenylmethyl group, and the pharmaceutical compositions in which they are present | |
| CN87100723A (zh) | 醌衍生物，它们的制备和使用 | |
| CN1034918A (zh) | 化学化合物 | |
| CN1832927A (zh) | 新型γ－分泌酶抑制剂 | |
| CN1473154A (zh) | 2,3-二氮杂萘酮衍生物 | |
| CN1436185A (zh) | 凝血酶受体拮抗药 | |
| CN86104664A (zh) | 取代的雄-1，4-二烯-3，17-二酮类化合物的制法 | |
| CN1050187A (zh) | 新的喹啉化合物及其制备方法 | |
| CN1182425A (zh) | 苯并咪唑化合物及其用作gabaa受体复合物调节器的用途 | |
| CN1349524A (zh) | 血管紧张肽原酶抑制剂 | |
| CN1209358C (zh) | αLβ2介导细胞粘连的抑制剂 | |
| CN1226248A (zh) | 用于抑制细胞增殖的取代的双吲哚基马来酰亚胺 | |
| CN1016169B (zh) | 制备药用咪唑衍生物的方法 | |
| EP0433149A2 (fr) | Antagonistes de la sérotonine, leur préparation et les médicaments les contenant | |
| CN1067892A (zh) | 新的吡咯并[2，3-b]吡啶衍生物的制备方法 | |
| CN1942437A (zh) | 作为环氧化酶－1－环氧化酶－2抑制剂的取代氮杂环丁烷化合物及其制备方法和作为药物的用途 | |
| CN86107695A (zh) | 不同的氮-取代的3-哌啶羧酸或氮-取代的3-吡啶羧酸及它们的衍生物 | |
| MXPA01000549A (es) | Compuestos de imidazol y su uso como inhibidores de adenosin desaminasa. | |
| CN1097006A (zh) | O-芳基吗啡喃的醚类化合物 | |
| EP1118610A1 (fr) | Nouveaux dérivés de benzènesulfonamide, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| CN87103528A (zh) | 1，3-二取代的咪唑盐类 | |
| CN1027066C (zh) | 吲哚衍生物的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C13 | Decision | ||
| GR02 | Examined patent application | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |